Over the past decade, one of the most remarkable breakthroughs in cancer therapy has been tumor immunotherapy, in particular immune checkpoint inhibitory programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) blockade (1). This evidence concerns the gene PDCD1 and cancer.